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LETTERS TO THE EDITOR
Alert to Physicians: Possible
Interaction of Aggrenox and Adenosine
A new medication, Aggrenox, a formulation of aspirin and
extended-release dipyridamole, is now being actively marketed to
physicians for the treatment of patients with transient ischemic
attacks and ischemic stroke. I believe that physicians involved in
pharmacological stress testing should recognize that patients tak-
ing this medicine may also be referred for an adenosine pharma-
cologic stress perfusion test. It would be anticipated that the
extended-release formulation of dipyridamole would antagonize
the breakdown of adenosine and, thereby, exaggerate adenosine’s
effects, including the induction of hypotension and atrial-
ventricular block. Patients receiving Aggrenox should not receive
adenosine but should receive dipyridamole instead. I believe the
readers of the Journal of the American College of Cardiology (JACC)
should be warned of the possible interaction of Aggrenox and
adenosine.
Steven R. Bergmann, MD, PhD
Department of Cardiology
Columbia University
College of Physicians & Surgeons
New York, New York 10032
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Pharmacists Agree:
Stop the Pharmacy Madness
I am writing in response to the editorial in the March issue of the
Journal of the American College of Cardiology (JACC) (1) concerning
the administrative challenges associated with insurance coverage
for prescription drugs which struck a resonant chord. As President
of the American Pharmaceutical Association (APhA), the national
professional society of pharmacists, I can assure you that my
profession is equally as frustrated with the inefficiencies and
unproductive hassles associated with many managed care programs
today. A recent study by Arthur Anderson shows that over 20% of
a pharmacist’s time is spent directly on activities related to
insurance issues (2). These include determining eligibility status,
resolving formulary and coverage issues and solving billing prob-
lems.
Because community pharmacies provide “point-of-service”
claims processing for prescription medications, pharmacists are
often placed in a difficult and undesirable position of mediating
insurance issues so that the patient can receive the prescribed
medication. Often, pharmacists must contact physicians for autho-
rization to change a patient’s medication to be compliant with the
plan formulary or to receive a prior authorization. These coverage
decisions are outside of the control of the pharmacist.
As you describe in your article, contacting the “help-desk” at an
insurance company is usually less-than-helpful. These call centers
are often understaffed with employees that are poorly trained and
unempowered to assist providers by authorizing clinical overrides.
This causes significant delays and often forces providers to make
decisions based on plan parameters as opposed to patient param-
eters.
I fully support the principles that you have outlined to “restore
rationality” to this process, but I suggest the addition of one
point—physicians and pharmacists must work together to ensure
changes in the design of health benefits that reduce the adminis-
trative burdens for all providers and, more importantly, facilitate
the efficient delivery of health care services to our patients.
As frustrating as these administrative barriers are to providers,
they are often even more frustrating and confusing for our patients.
Physicians and pharmacists must work toward building a medica-
tion delivery system where “care” is more important than “cover-
age.”
As you know, there are many other health care delivery issues we
could discuss but I am, as usual, tied up on the phone trying to
obtain authorization for Mrs. Brown’s heart medication which is,
not surprisingly, unavailable on her health care plan’s formulary.
Robert D. Gibson, PharmD
American Pharmaceutical Association
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The Pharmacy Perspective
on Managed Care Madness
I share your frustrations regarding the barriers to patient care as
described in your editorial entitled, “Pharmacy Madness” (JACC
2000;35:802–3). However, as a Doctor of Pharmacy (PharmD), I
find your description of the issue disturbing. The profession of
pharmacy is no more in control of the barriers you described than
the medical profession. Consistent with your description of your
P&T Committee experience, Managed Care permits medical
decisions (such as formulary inclusion or exclusion) to be made
based upon business cases and not patient risk versus benefit. This
is further perpetuated by patients’ willingness to enroll in (and thus
support) such healthcare organizations coupled with their lack of
willingness to pay for diagnostics or treatments not covered by
their plans.
Clinical pharmacists in the hospital setting are under many of
the same Managed Care pressures that physicians find themselves
under in that there is constant pressure to evaluate the costs most
closely tied to their function; while this correlates in part to
diagnostic procedures for physicians, it correlates to medications
for pharmacists. There is clearly a lack of understanding of the
clinical pharmacist’s expertise given that you view your institution’s
pharmacist as nothing more than a “SWAT team whose goal is to
reduce inpatient pharmaceutical costs in specific areas.”
Community pharmacists practicing in a retail setting are under
similar constraints. As pharmacists whose current primary role is to
dispense medication and advise regarding those medications, they
often find themselves as an involuntary liaison between the
insurance plans and the patients who chose to enroll in them.
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Allow me to ensure you that pharmacy curriculums do not provide
background as an insurance broker, nor do pharmacists desire to be
in such a position. This environment is one of the principle reasons
for the current shortage of retail pharmacists. This is heightened by
the standardization of the Doctor of Pharmacy degree and its
replacement of the Bachelor of Science curriculums nationwide.
Pharmacists today go through 6 to 7 years of education whose
foundation prepares students to practice pharmaceutical care in a
clinical setting. It is nothing short of degrading to be forced by
Managed Care to assume responsibility for poor medical decisions
justified by business cases.
So, allow me to assure you as a pharmacist that I am equally
frustrated by the constraints of Managed Care on the clinician’s
ability to decide what is best for the patient. However, change will
only be achieved when Managed Care is forced to change. Perhaps
this is an endeavor on which physicians and pharmacists should
collaborate since the goal of both professions is to optimize patient
care.
Liza Weiss, PharmD, RPh
817 Tennent Road
Manalapan, New Jersey 07726
E-mail: lwpharmd@earthlink.com
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Coronary Anatomy in Acute
Myocardial Infarction Patients
With Sudden Out-Of-Hospital Death
The recent article by Gheeraert et al. (1) was interesting and
thought-provoking. The authors suggested that acute occlusion of
the left-side coronary vessels (left anterior descending [LAD] or
left circumflex [Lcx] arteries) increases the risk of out-of-hospital
ventricular fibrillation (VF) in acute myocardial infarction (AMI)
patients. The study was designed so that they compared patients
who were successfully resuscitated from VF found to be due to
AMI and AMI patients without VF. Their conclusions, however,
raise points of criticism.
The resuscitated patients they studied with angiography were
those in whom there was a reasonably short period from the loss of
consciousness to the beginning of resuscitation to assure that these
patients had a chance of surviving without major neurologic
deficits. The authors also discuss the possible limitation by
selection bias because a great majority of patients with out-of-
hospital VF fall short of reaching their series (2). However, they
hypothesize that there is no bias without referring to previous
studies on sudden cardiac death (SCD) victims.
The authors found that only 15% of occlusions in those AMI
patients succesfully resuscitated from VF were situated in the right
coronary artery (RCA). This finding is contradicted by the fact
that numerous studies on SCD victims with AMI have shown that
RCA is the culprit occluded artery in 40 to 50% of cases (2–5).
One study even addressed the issue of coronary and myocardial
findings in SCD victims compared with hospital AMI patients (3)
and found that inferior infarctions and RCA occlusions were more
frequent in SCD victims.
It is, thus, highly likely that the results of Gheeraert et al. (1) are
the consequence of selection bias. Their conclusion that RCA
occlusion is associated with decreased risk of arrhythmia is also
highly speculative in light of the patient selection and the results of
previous studies on SCD. In asymptomatic individuals who suffer
AMI, the degree of the underlying coronary disease is the most
severe in the left-sided vessels, especially LAD (6). Thus, collat-
erals are possibly more frequently supplying the myocardium
normally fuelled by LAD, and the total occlusion of RCA is likely
to be associated with severe arrhythmic response in the absence of
significant collaterals (7).
The major conclusion from the results presented in the study by
Gheeraert et al. is that left-side coronary occlusion may, in fact, be
associated with decreased risk of dying suddenly in the acute phase
of AMI and select individuals who are more likely to be resusci-
tated succesfully by the paramedics and ultimately reach the
hospital and qualify for study series, such as the one commented on
here.
Jussi Mikkelsson, MD
Department of Forensic Medicine
Medical School/B-building, University of Tampere
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REPLY
We thank J. Mikkelsson for his comments on our article (1). The
authors would like to take this opportunity to discuss the effects of
patient selection and points of interest in more detail when our
results are compared with studies on sudden cardiac death (SCD).
We studied out-of-hospital ventricular fibrillation (VF) in the
early phase of acute myocardial infarction (AMI). To compare our
study with studies on SCD, two main points deserve attention.
First, we focused on the early phase of AMI. In victims of SCD
identification of subjects that were in the early phase of AMI is
extremely challenging. Standard histological techniques underes-
timate the true frequency of early AMI. The articles on SCD cited
by Mikkelsson confirmed that only 5 to 21% of victims were in the
early phase of AMI. Presence of a fresh coronary occlusion or
ruptured plaque also varied between 23 and 82%, reflecting
heterogeneity of methodology or studied populations. Diagnosis of
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